• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Parathyroid and bone response of the diabetic patient to uremia.

作者信息

Vincenti F, Arnaud S B, Recker R, Genant H, Amend W J, Feduska N J, Salvatierra O

出版信息

Kidney Int. 1984 Apr;25(4):677-82. doi: 10.1038/ki.1984.73.

DOI:10.1038/ki.1984.73
PMID:6482171
Abstract

Biochemical and radiologic indices of bone disease were assessed in 26 insulin-dependent diabetic patients and 28 nondiabetic patients with endstage kidney disease. The two groups were comparable in age, sex, duration of renal failure, and length of time on dialysis. Diabetic patients showed significantly lower serum calcium and immunoreactive parathyroid hormone (iPTH) levels than nondiabetic patients. iPTH was not related to total serum calcium, but was positively correlated with serum phosphorous (r = 0.37, P less than 0.05 and r = 0.54, P less than 0.005, in nondiabetic and diabetic patients, respectively). iPTH correlated with alkaline phosphatase (r = 0.59, P less than 0.0009) and calcitonin (r = 0.51, P less than 0.05) only in nondiabetic patients. Osteitis fibrosa was noted radiologically in 30% of nondiabetic patients and in none of the diabetic patients (P less than 0.03). Bone morphology in eight diabetic patients who underwent iliac bone biopsy was characterized by reduced trabecular and osteoid bone volume, no woven bone, and marked reduction in indices of bone formation and resorption. The small amount of bone and lack of osteomalacia are a unique feature of the diabetic patient with chronic renal disease. The long-term sequelae of low bone turnover and reduced circulating iPTH may present a special problem to the long term diabetic survivor on the current therapies of uremia.

摘要

相似文献

1
Parathyroid and bone response of the diabetic patient to uremia.
Kidney Int. 1984 Apr;25(4):677-82. doi: 10.1038/ki.1984.73.
2
Bone changes in end-stage oxalosis.
AJR Am J Roentgenol. 1981 May;136(5):935-9. doi: 10.2214/ajr.136.5.935.
3
Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.甲状旁腺功能亢进症和肾性骨营养不良中的胰岛素样生长因子系统成分。
Kidney Int. 2000 Feb;57(2):423-36. doi: 10.1046/j.1523-1755.2000.00862.x.
4
Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.新诊断的晚期透析前糖尿病肾病患者慢性肾脏病相关矿物质骨异常的概况:一项基于医院的横断面研究。
Diabetes Metab Syndr. 2017 Dec;11 Suppl 2:S931-S937. doi: 10.1016/j.dsx.2017.07.019. Epub 2017 Jul 8.
5
Surgically induced uremia in rats. I: Effect on bone strength and metabolism.
Biosci Rep. 1993 Oct;13(5):275-87. doi: 10.1007/BF01137964.
6
Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis.接受血液透析的糖尿病患者继发性甲状旁腺功能亢进症减轻。
JAMA. 1981 Mar 6;245(9):930-3.
7
Qualitative bone defect in uremic osteosclerosis.尿毒症性骨硬化症中的定性骨缺损
Metabolism. 1982 Aug;31(8):805-11. doi: 10.1016/0026-0495(82)90079-8.
8
Decreased mineralization in hemodialysis patients after subtotal parathyroidectomy.甲状旁腺次全切除术后血液透析患者骨矿化减少。
Calcif Tissue Int. 1982 Jan;34(1):16-20. doi: 10.1007/BF02411202.
9
Azotemic renal osteodystrophy; clinical features and bone pathology.
Endocrinol Jpn. 1979 Jun;26(Suppl):85-93. doi: 10.1507/endocrj1954.26.supplement_85.
10
Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients.
Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S139-42. doi: 10.1053/ajkd.2001.27423.

引用本文的文献

1
Fibroblast growth factor 23 as a risk factor for incident diabetes.成纤维细胞生长因子23作为新发糖尿病的一个风险因素。
Curr Opin Nephrol Hypertens. 2025 Jul 1;34(4):284-290. doi: 10.1097/MNH.0000000000001078. Epub 2025 Apr 15.
2
Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors.肾病患者的贫血与矿物质骨代谢紊乱:成纤维细胞生长因子-23及其他相关因素的作用
Int J Mol Sci. 2024 Nov 29;25(23):12838. doi: 10.3390/ijms252312838.
3
Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony.
成纤维细胞生长因子 23 与 2 型糖尿病不良临床结局:苦乐参半的交响曲。
Curr Diab Rep. 2020 Aug 28;20(10):50. doi: 10.1007/s11892-020-01335-7.
4
Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.依特卡肽用于接受血液透析的糖尿病患者的临床及药理学方面的理论概述。
Drug Des Devel Ther. 2018 Apr 19;12:901-909. doi: 10.2147/DDDT.S160223. eCollection 2018.
5
Adynamic bone disease-bone and beyond.动力缺失性骨病——骨骼及其他方面
NDT Plus. 2008 Jun;1(3):135-47. doi: 10.1093/ndtplus/sfn040.
6
Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients.甲状旁腺激素全段迅速下降可预测血液透析患者对西那卡塞的反应更好。
Yonsei Med J. 2013 Mar 1;54(2):453-63. doi: 10.3349/ymj.2013.54.2.453.
7
Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease.糖尿病合并慢性肾脏病患者矿物质代谢紊乱的发病更早、程度更重。
Diabetes Care. 2012 May;35(5):994-1001. doi: 10.2337/dc11-2235. Epub 2012 Mar 23.
8
Associations between serum leptin level and bone turnover in kidney transplant recipients.血清瘦素水平与肾移植受者骨转换的关系。
Clin J Am Soc Nephrol. 2010 Dec;5(12):2297-304. doi: 10.2215/CJN.03520410. Epub 2010 Aug 5.
9
Bone and mineral disorders in pre-dialysis CKD.透析前慢性肾脏病患者的骨与矿物质紊乱
Int Urol Nephrol. 2008;40(2):427-40. doi: 10.1007/s11255-008-9346-7.
10
Osteodystrophy of diabetics in chronic dialysis: a histomorphometric study.
Calcif Tissue Int. 1988 May;42(5):297-301. doi: 10.1007/BF02556363.